Alpha Omega Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Alpha Omega Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12	Closed	-$2K	–	544
2019 Q2	$2K	Hold	12	–	–	﹤0.01%	576
2019 Q1	$2K	Buy	+12	New	+$2.22K	﹤0.01%	540

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alpha Omega Wealth Management's VRTX Position: Q3 2019 in Review

Alpha Omega Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 12 shares — an estimated $2K sold.

Alpha Omega Wealth Management first reported a position in VRTX in Q1 2019 and held it in 2 quarters. The position peaked at $2K in Q2 2019. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Alpha Omega Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Alpha Omega Wealth Management sold 12 Vertex Pharmaceuticals shares in Q3 2019, an estimated $2K.
Alpha Omega Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 2 quarters.
Alpha Omega Wealth Management's Vertex Pharmaceuticals position peaked at $2K in Q2 2019.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Alpha Omega Wealth Management's 13F filing for Q3 2019, filed 12 Nov 2019.